WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > DNA Services of America
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
MedTech
Ligand Pharmaceuticals | July 29, 2021
Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions. The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...
Industrial Impact
Ecological Laboratories, Inc. | July 08, 2022
Ecological Laboratories, Inc. a Biotechnology company that develops and manufactures novel, proprietary, liquid microbial formulations capable of solving many of the most challenging environmental problems, announced that it has acquired TOMCO Chemical. TOMCO Chemical has provided bacterial products specifically to breakdown solids and reduce odors for Hog Farms in the United States. "We are thrilled to bring together the TOMCO team with Ecological, whic...
Medical, Industry Outlook
Businesswire | August 02, 2023
Replimune Group, Inc. a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. “We are excited to enter into this collaboration with Incyte to explo...
Solvias | July 18, 2022
Solvias, one of the world's leading independent pharmaceutical testing and manufacturing companies, announced today that it has acquired Utrecht, Netherlands-based Cergentis. The acquisition bolsters Solvias' platform of biologics and cell and gene therapy testing solutions. According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more resear...
Article
infographic
Video
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE